Find out how ENSPRYNG was studied
ENSPRYNG is the only neuromyelitis optica spectrum disorder (NMOSD) therapy proven in two clinical studies
ENSPRYNG is the only neuromyelitis optica spectrum disorder (NMOSD) therapy proven in two clinical studies
Two clinical trials were conducted to determine whether ENSPRYNG alone or ENSPRYNG in combination with immunosuppressive therapy (IST) could lower the risk of relapse in adults with NMOSD vs placebo. ISTs may stop some activity in your body’s immune system, and can include azathioprine, mycophenolate mofetil, or oral corticosteroids. Both trials also measured how many patients were relapse-free at specific time points with treatment.
Patients from countries around the world participated in the 2 trials.
A wide range of patients in terms of age, gender, AQP4-IgG status, and severity of disease were represented in the clinical trials:
Study 1 excluded patients who were recently taking other treatments before starting the trial. The study included 95 patients who were AQP4-IgG(+) or AQP4-IgG(–) to randomly receive either ENSPRYNG or placebo. Of the 64 who were AQP4-IgG(+), 41 patients received ENSPRYNG and 23 patients received placebo.
Study 2 only included patients who were taking certain ISTs (azathioprine, mycophenolate mofetil, or oral corticosteroids) before starting the trial. The study included 76 patients who were AQP4-IgG(+) or AQP4-IgG(–) to randomly receive either ENSPRYNG plus IST or placebo plus IST. Of the 52 who were AQP4-IgG(+), 26 patients received ENSPRYNG and 26 patients received placebo.
ENSPRYNG is only approved for AQP4-IgG(+) adults.
Get the details around how ENSPRYNG may work in NMOSD
The information contained in this section of the site is intended for US healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.